Quantcast

Latest Alseres Pharmaceuticals Inc. Stories

2009-09-10 08:54:00

NEW YORK, Sept. 10 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. US and European Radiopharmaceuticals Market http://www.reportlinker.com/p0109914/US-and-European-Radiopharmaceuticals-Market.html This report analyzes the US and the European markets for Radiopharmaceuticals in Millions of US$. The major product segments analyzed are Diagnostic Radiopharmaceuticals, and Therapeutic Radiopharmaceuticals. Annual forecasts are...

2009-05-07 10:15:00

HOPKINTON, Mass., May 7 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE; Alseres) announced today that effective on Friday, May 8, 2009 trading in its shares on the NASDAQ Capital Market will be suspended. Effective at the same time, Alseres common stock will be available for quotation on the Pink Sheets under the ticker ALSE. Alseres will also seek to have its common stock traded on the OTC bulletin board. (Logo:...

2009-04-30 08:00:00

HOPKINTON, Mass., April 30 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE; the Company) announced today that on April 24, 2009 it entered into an Amendment to License Agreement (Amendment) with BioAxone Therapeutic, Inc. (BioAxone), pursuant to which the license agreement between the Company and BioAxone originally executed in December 2006 and amended in March 2007 (the Cethrin License) was further amended. The Amendment replaces all of the pre-commercial financial...

2009-04-14 13:11:00

HOPKINTON, Mass., April 14 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) announced that on April 9, 2009 it received a NASDAQ Staff Determination indicating that the Company has not regained compliance with the minimum $35 million market value of listed securities requirement set forth in NASDAQ Marketplace Rule 4310(c)(3)(B) (the "Rule"), and that, accordingly, the Company's common stock will be delisted from The NASDAQ Capital Market unless the Company requests an...

2009-04-06 15:50:00

Agreement opens clear path to NDA for early diagnosis of Parkinsonian Syndromes HOPKINTON, Mass., April 6 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) announced today that it has reached agreement with the US Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for the Phase III protocol of Alseres' Altropane(R) Molecular Imaging Agent to aid in the early diagnosis of Parkinsonian syndromes including Parkinson's disease. A SPA...

2009-03-31 15:20:00

HOPKINTON, Mass., March 31 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that the report of the Company's independent registered public accounting firm regarding the Company's 2008 financial statements contained an explanatory paragraph regarding the Company's ability to continue as a going concern. NASDAQ Marketplace Rules require NASDAQ-traded companies to publicly announce if their Annual Report on Form 10-K includes an audit report containing a...

2009-03-26 10:36:00

HOPKINTON, Mass., March 26 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that they will host a conference call on Wednesday, April 1st at 9:00am EDT to review 2008 results. (Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO ) To access the conference call, please dial 1-877-856-1968 for domestic and 1-719-325-4770 for international calls. The code for this conference call is 2264513. Please dial in 5 to 10 minutes prior to the...

2009-02-27 08:10:00

HOPKINTON, Mass., Feb. 27 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE), today announced that on February 24, 2009 it entered into a securities purchase agreement (the "Agreement") with Cato Holding Company (d/b/a Cato BioVentures) for the private placement of 200,000 shares of common stock of the Company at a purchase price of $1.00 per share. The financing resulted in total gross proceeds of $200,000. The Company intends to use the net proceeds from this private...

2009-02-03 13:40:00

HOPKINTON, Mass., Feb. 3 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE), announced today that it has completed enrollment in the first stage of the Altropane Parkinson's or Essential Tremor (POET-2) Phase III clinical program. The objective of the first part of the program was to acquire the set of Altropane images which will be used to train expert readers for the Phase III registration portion of the program. The Altropane molecular imaging agent is being developed...


Word of the Day
cock-a-hoop
  • Exultant; jubilant; triumphant; on the high horse.
  • Tipsy; slightly intoxicated.
This word may come from the phrase 'to set cock on hoop,' or 'to drink festively.' Its origin otherwise is unclear. A theory, according to the Word Detective, is that it's a 'transliteration of the French phrase 'coq a huppe,' meaning a rooster displaying its crest ('huppe') in a pose of proud defiance.' Therefore, 'cock-a-hoop' would 'liken a drunken man to a boastful and aggressive rooster.'
Related